What is Thymosin Alpha-1?

Thymosin alpha-1 (Tα1), also written thymalfasin and thymosin α-1, is a thymus-derived peptide hormone studied primarily as an immunomodulatory agent. It is a 28-amino-acid acetylated peptide, and the literature describes it as a non-canonical ligand for the Hypocretin (Orexin) Receptor 1 (HCRTR1), a classical neuropeptide receptor expressed on neurons [1]. Research on Thymosin Alpha-1 spans immune reconstitution, vaccine response, oncology combination regimens, and, more recently, direct neuroprotection.

Work in this area centres on the HCRTR1 receptor axis and on downstream signalling through Receptor-Interacting Protein Kinase 3 (RIPK3), the central executioner of necroptosis [1]. Separate lines of investigation address T-cell differentiation, dendritic cell and macrophage activity, and thymic output [3].

Research Studies

Thymosin Alpha-1 and HCRTR1-mediated suppression of neuronal necroptosis

In a study of the thymus-to-CNS axis, Tα1 was identified as a non-canonical ligand for HCRTR1. Engagement of this receptor shielded neurons from cell death by suppressing RIPK3 activity, the central executioner of necroptosis [1]. The work describes a direct neuroprotective axis linking the thymus to the central nervous system, and reports that the physiological relevance of this pathway was highlighted in the findings [1]. This is a mechanistic finding; it does not establish a clinical neuroprotective effect in humans.

Thymosin Alpha-1 and immune-related adverse events from checkpoint inhibitor combination therapy

A case report described a nasopharyngeal carcinoma patient who developed multisystem immune-related adverse events (irAEs) after treatment with sintilimab, a PD-1 inhibitor, in combination with Tα1. The patient presented with high fever, rash, interstitial pulmonary edema, and multiple organ failure [2]. The authors analysed the treatment course and regression and discussed risks and management strategies for combining immune checkpoint inhibitors with immunomodulators, highlighting the need for clinical vigilance against possible immune overactivation triggered by combination therapy [2].

Thymosin Alpha-1 and T-cell differentiation in aging

Aging is characterised by immune decline, mainly due to thymic involution, the age-related shrinkage of the thymus gland, which leads to reduced T-cell production, chronic inflammation, and increased susceptibility to age-related diseases [3]. Tα1 has been reported to exhibit immunomodulatory, anti-inflammatory, and antioxidant properties, and to help restore immune function by stimulating T-cell differentiation, enhancing thymic output, and modulating dendritic cell and macrophage activity [3]. Preclinical and clinical studies cited in that review report that Tα1 can improve vaccine response in the elderly and mitigate immunosenescence [3].

Thymosin Alpha-1 and irAEs secondary to immune checkpoint inhibitors

A registered clinical trial is exploring whether Tα-1 could be used as a therapeutic option for the treatment of immune-related adverse events secondary to immune checkpoint inhibitors. The rationale given is that Tα-1 has shown clinical benefits in patients whose immune functions are severely compromised or ineffective [4]. This is a trial record; no outcome data are reported in the evidence available here.

Thymosin Alpha-1 and immunoinflammatory subtyping in acute aortic dissection

Acute aortic dissection has an acute onset and high mortality, with immunoinflammatory response driving lesion progression, and current perioperative anti-inflammatory therapies are described as mostly empirical and poorly targeted [5]. A prospective multicentre randomised controlled trial plans to enrol 300 patients, randomly divided into two groups, with the experimental group receiving subtyping-based precision therapy and the control group receiving empirical strategies [5]. Tα1 appears within this broader precision-immunotherapy framework rather than as the trial's primary intervention.

Thymosin Alpha-1 (thymalfasin) and neoadjuvant treatment of esophageal cancer

A prospective, single-arm, multicentre clinical study conducted in China is enrolling patients with pathologically or cytologically confirmed resectable esophageal squamous cell carcinoma to explore the efficacy and safety of adebrelimab combined with thymalfasin and chemotherapy as neoadjuvant therapy [6]. The study consists of a screening period, a treatment period including neoadjuvant therapy and surgery, and a follow-up period comprising safety follow-up and survival follow-up [6].

Thymosin Alpha-1 and recurrent implantation failure

A clinical trial is evaluating the safety and efficacy of Tα1 as an adjunctive immunomodulatory therapy in women with unexplained recurrent implantation failure undergoing IVF/ICSI cycles [7]. This is a trial record; results are not reported in the evidence available here.

Thymosin Alpha-1 and soft tissue sarcoma combination regimens

A prospective, multicentre, open-label, single-arm phase II study is evaluating spatially fractionated radiotherapy combined with a multi-agent strategy in soft tissue sarcoma, with primary objectives covering clinical prognosis and adverse events encountered during treatment [8]. The regimen described includes Toripalimab and recombinant human granulocyte-macrophage colony-stimulating factor alongside the radiotherapy component [8]. Tα1 is not the focus of this record.

Thymosin Alpha-1 and chemotherapy-induced antitumor immunity

Chemotherapy induces cancer cell apoptosis and the release of apoptotic bodies that are poorly immunogenic or immunosuppressive, creating a barrier to coadministered or second-line immunotherapies [9]. In that study, circulating levels of Tα-1 were found to be reduced, and the peptide was reported to restore chemotherapy-induced antitumor immunity by chaperoning a microRNA ligand of TLR7 in dendritic cells [9].

Thymosin Alpha-1 in unresectable hepatocellular carcinoma

A retrospective study set out to validate the efficacy and safety of Tα-1 combined with lenvatinib plus sintilimab in the treatment of unresectable hepatocellular carcinoma, in patients treated at a single hospital in Guangxi Zhuang Autonomous Region [10].

Thymosin Alpha-1 in thyroid and endocrine contexts

Thyroid disorders, particularly autoimmune conditions such as Hashimoto's thyroiditis, are frequently associated with persistent systemic symptoms despite biochemical normalisation with standard hormone replacement, prompting investigation into adjunctive strategies targeting immune, metabolic, and neuroendocrine pathways [11].

Comparison of evidence contexts

If you are reading this for personal health reasons

This material is sold for laboratory research use only. We do not provide dosing or medical guidance, and nothing here is a recommendation for human use. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

• [1] Thymosin Alpha-1 Provides Direct Neuroprotection by Engaging the Orexin Receptor HCRTR1 to Suppress Neuronal Necroptosis — https://pubmed.ncbi.nlm.nih.gov/42693587/
• [2] A Case Report of a Multisystemic Immune-Related Adverse Event Caused by Sintilimab in Combination With Thymosin Alpha-1 — https://europepmc.org/article/PMC/PMC12883329
• [3] Aging and Thymosin Alpha-1 — https://europepmc.org/article/PMC/PMC12692621
• [4] Thymosin Alpha-1 for irAE Secondary to ICIs — https://clinicaltrials.gov/study/NCT06178146
• [5] AI-assisted Subtyping-directed Precision Treatment in Acute Aortic Dissection — https://clinicaltrials.gov/study/NCT07382375
• [6] Study of Adebrelimab Combined With Thymalfasin and Chemotherapy for Neoadjuvant Treatment of Esophageal Cancer — https://clinicaltrials.gov/study/NCT07780721
• [7] Thymosin-α1 for Recurrent Implantation Failure — https://clinicaltrials.gov/study/NCT07675980
• [8] A Prospective, Multicenter, Open-label, Single-arm Phase II Clinical Study Evaluating the Efficacy and Safety of Spatially Fractionated Radiotherapy Combined With the PraG Strategy for the Treatment of Soft Tissue Sarcoma — https://clinicaltrials.gov/study/NCT07342322
• [9] Thymosin Alpha-1 Restores Chemotherapy-Induced Antitumor Immunity by Chaperoning a MicroRNA Ligand of TLR7 in Dendritic Cells — https://pubmed.ncbi.nlm.nih.gov/42295795/
• [10] The efficacy and safety of thymosin alpha-1 combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a retrospective study — https://europepmc.org/article/PMC/PMC12015295
• [11] Peptide Therapies in Thyroid Health: Emerging Applications in Endocrine and Immune Modulation — https://pubmed.ncbi.nlm.nih.gov/42222211/